Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. is a U.S.-based biotechnology company focused on developing T-cell therapies and related platform technologies for infectious diseases, cancer, and neurological disorders. Its core programs include TVGN 489 and the ExacTcell technology platform, supported by Tevogen.AI and a portfolio of intellectual property.

18

0.22

0.10

— Tevogen Bio Holdings Inc.
%
Clinical-stage product candidates0% Cell therapy candidates under preclinical and clinical development, including TVGN 489.
Platform technology0% ExacTcell technology used to identify and develop antigen-specific T-cell therapies.
AI-enabled discovery tools0% Tevogen.AI tools used to support target selection, discovery, and development workflows.
Intellectual property0% Issued patents, pending applications, and trademarks tied to the company’s technologies.

Tevogen Bio does not yet have commercial product customers; its near-term end users are expected to be patients treated...

  • Patientsprimary

    End beneficiaries of TVGN 489 and other future cell therapy candidates for infectious, oncology, or neurological indications.

  • Hospitals and specialty providersprimary

    Clinical settings that would administer approved therapies and manage patient access.

  • Clinical research organizations and trial sitessecondary

    Buy development services and support trial execution, data collection, and regulatory studies.

  • Manufacturing and supply partnerssecondary

    Provide lab, process development, and manufacturing capabilities needed for cell therapy scale-up.

  • Potential commercial partners and payorsemerging

    Relevant for future licensing, reimbursement, and market access once products are commercialized.

Tevogen Bio is headquartered in the United States and conducts its research, intellectual property, and facility...

  • •Headquartered and operated in the United States
  • •Research and laboratory operations centered in New Jersey
  • •Former laboratory facility in Philadelphia, Pennsylvania
  • •U.S. patent portfolio and trademark filings
  • •Future commercialization would initially depend on U.S. approvals

Tevogen Bio’s strategy is to advance its cell therapy pipeline through preclinical work, clinical trials, and...

01
Advance TVGN 489 developmentshort-term

Clinical and regulatory progress is required before any product revenue can be generated.

02
Build manufacturing capabilityshort-term

Cell therapies require specialized production, quality control, and supply chain infrastructure.

03
Broaden the pipeline with platform technologiesmedium-term

ExacTcell and Tevogen.AI can support additional candidates and reduce dependence on one program.

04
Protect intellectual propertylong-term

Patents and trademarks are central to exclusivity and future partnering value.

Tevogen Bio is a development-stage biotechnology company with no product revenue to date, so its business depends on...

critical

Clinical and regulatory failure

Drug candidates may not demonstrate safety, efficacy, or manufacturability required for approval.

Scope
TVGN 489 and future pipeline
Materiality
high
high

No commercial revenue yet

The company depends on future approval and launch of TVGN 489 or another candidate before sales begin.

Scope
Entire business model
Materiality
high
high

Manufacturing execution risk

Cell therapy production requires specialized infrastructure, quality systems, and supply reliability.

Scope
Commercial launch readiness
Materiality
high
high

Nasdaq listing and liquidity risk

Failure to maintain listing standards could reduce trading liquidity and investor access.

Scope
Public market access
Materiality
medium
medium

Legal and transaction-related uncertainty

The company disclosed potential legal proceedings related to the business combination.

Scope
Corporate structure and disclosures
Materiality
medium
Fair value measurements
Reported earnings and balance sheet values
Stock-based compensation
Operating expenses and dilution
Accrued expenses
Quarterly expense recognition
Operating leases
Balance sheet, cash flow, and occupancy costs

Generation Bio Co.

Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

PepGen Inc.

PEPG · Pharmaceutical Preparations

PRECIGEN, INC.

PGEN · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

IN8BIO, INC.

INAB · Biological Products, (No Diagnostic Substances)

: 29/04/2026